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A B S T R A C T
Nonmelanoma skin cancer (NMSC) is the most common cancer worldwide and the most frequently
observed malignancy in whites. Approximately 75% to 80% are basal cell carcinomas and 20% to
25% are squamous cell carcinomas. Incidence is increasing, partly reflecting an ageing population, and
NMSC is more commonly seen in men. The predominant causative agent is ultraviolet solar radiation
exposure, with the majority of cases occurring on the head and neck. Surgical excision is typically the
treatment of choice, providing histopathologic information, high cure rates, and acceptable cosmetic
and functional outcomes. Radiation therapy is reserved for cases where surgery is not the preferred
choice or for high-risk cases where adjuvant therapy is recommended. Although overall mortality rates
are low, patients with complex cases such as those with immunosuppression should be considered
for management within multidisciplinary tumor boards. In contrast, Merkel cell carcinoma is a rare and
aggressive malignancy, frequently arising on the head and neck in older whites, with a poorer
prognosis. This article focuses on the current evidence guiding practice, recent advances, and areas of
controversy in NMSC and Merkel cell carcinoma of the head and neck.
J Clin Oncol 33:3338-3345. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Nonmelanoma skin cancer (NMSC) is the most
common cancer worldwide, with incidence varying
depending on country and latitude. It represents a
major global economic and health burden. More
than 2.5 million individuals in the United States are
diagnosed with a NMSC each year, with basal cell
carcinomas (BCCs) accounting for approximately
75% to 80% and cutaneous squamous cell carcino-
mas (cSCCs) approximately 20% to 25%. Amajor-
ity (80% to 90%) occur on the sun-exposed areas of
the head and neck (HN).1,2
NMSCs can be divided into low and high risk,
based on the presence of prognostic factors and risk
of local, regional, and distant relapse. The distinc-
tion is part of a continuum and hence somewhat
arbitrary, with many of the prognostic factors pre-
dicting for local recurrence also predicting for re-
gional recurrence and the uncommon event of
distant relapse.3,4 Approximately 5% of patients
withNMSC,mainly thosewith cSCC,will have clin-
icopathologic features that predict for an increased
risk of recurrence.2
Although mortality rates are higher in cSCC,
the overall rate is low, with immunosuppression
increasing the incidenceof relapse anddeath inboth
cSCC and BCC.5 The treatment of NMSC, particu-
larly in the advanced stage, is an area where high-
level evidence guidingmanagement is lacking, and it
is therefore basedmainly on retrospective series and
low-level systematic reviews.TheNationalCompre-
hensive Cancer Network (NCCN) has established
consensus guidelines through a working group and
recommends patients with complex cases seek con-
sultation from a multidisciplinary tumor board.4
Merkel cell carcinoma (MCC) is a rare and aggres-
sive malignancy, frequently arising on the HN in
older whites; it is more commonly seen in women.6
This article focuses on the current evidence
guiding practice, recent advances, and areas of con-
troversy in NMSC and MCC of the HN. Detailed
histopathologic descriptions, screening and preven-
tion, and management of benign, premalignant,
andother skinmalignancies are beyond the scope of
this article.
CSCC
Etiologic Factors
Common risk factors include skin phenotype,
cumulative ultraviolet (UV) solar radiation expo-
sure, and immunosuppression.7 Other factors
include genetic conditions such as xeroderma pig-
mentosum, chemical exposure such as arsenic,
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chronic ulcers and scars, tobacco use (particularly of lip), therapeutic
ionizing radiation, and human papilloma virus infection.7,8 p53 mu-
tations are found in 50% to 100% of NMSCs as a result of UV
exposure, supporting a role in carcinogenesis.9
Clinical Features and Diagnostic Workup
Because cSCCs commonly arise from chronically sun-exposed
areas and solar keratoses, early diagnosis of invasive cSCC can be
difficult. Ina studybyGreenet al,10 theearlydiagnosis accuracy rateby
a cohort of experienced dermatologists was found to be 39%.
After histopathologic confirmation, diagnostic imaging such as
computed tomography (CT) or magnetic resonance imaging (MRI)
to assess local disease extent, regional lymph node involvement, or
presence of distantmetastases is performed when clinically indicated.
Positron emission tomography (PET) has proven useful in staging of
mucosal HNSCC (mHNSCC), and although studies are lacking, it is
likely that PET has a similar utility in locoregionally advanced cSCC.
Staging and Prognostic Factors
T stage. The Union for International Cancer Control (UICC)
and the American Joint Committee on Cancer (AJCC) published
revised TNM skin cancer staging classifications in 2009 and 2010,
respectively.11,12 These classifications base early T stage (T1/2) on size
criteria ( 2 v  2 cm in greatest dimension), with more advanced
disease (T3/T4) reflecting invasion into surrounding structures and
perineural invasion (PNI) of skull base. To improve its prognostic
value, the AJCC further defines T stage based on the presence of
high-risk features (T1 two and T2 two high-risk factors). These
features have been determined on the available evidence and findings
frommultivariableanalyses. Inaddition to size (2cm), they include:
 2 mm thickness, Clarke level  4, PNI, primary site (ears, non–
hair-bearing lip), and poor differentiation.11,12
Clayman et al13 reported a reduction in disease-specific survival
(DSS) in patientswith local recurrence at presentation, increasing size
and depth, invasion beyond subcutaneous tissues, and PNI. Patients
with  one risk factor compared with no risk factors had a signifi-
cantly inferior 3-year DSS (70% v 100%).
Althoughboth theAJCCandUICC staging systems are relatively
simple to apply, someaspects limit their utility.UICCT1classification
is solely based on size and therefore may not account for poor out-
comes in some early-stage tumors that harbor high-risk features.14
The Brigham andWomen’s Hospital reported outcomes based on
an alternative staging system, assigning T stage solely on number of
risk factors (T1, zero; T2a, one; T2b, two to three; T3, four risk
factors or bone invasion). It concluded its staging classification
resulted in improved prognostication, with T2b/T3 tumors defin-
ing a high-risk group.14
N stage. Previously, N stage was based on the absence or pres-
ence of involved lymph nodes (N0-N1). This failed to capture impor-
tant information regarding number, size, and location of involved
nodes. The current system now reflects N staging similar to that for
mHNSCC. Some authors have also proposed further refinement by
differentiating intraparotid and cervical nodal involvement.15 Prog-
nostic factors and risk stratification forNMSCof theHNare summa-
rized in Table 1.
Treatment
Figure 1 shows the treatment algorithm for primary site.
Local. The preferred treatment modality is dependent on site,
extent of disease, comorbidities, and patient preference. Ninety-five
percent of cSCCs are low risk, with surgery typically the treatment of
choice, providing histopathologic evaluation, high cure rates, and
acceptable cosmetic and functional outcomes. Mohs micrographic
surgery (MMS) is a technique that provides excellent control rates
while aiming to remove the least amountof normal tissuenecessary to
obtain clear margins. Leibovitch et al16 reported a 5-year recurrence
ratewithMSSof 2.6%.However, its broad applicability for allNMSCs
remains questionable because of a lack of randomized evidence dem-
onstrating its superiority over standard surgery for simple lesions,
coupled with the additional time, capital, and expense required.17
Thus, MMS is generally favored for selected lesions, such as those
involving poorly defined borders, location in anatomically sensitive
areas (eg, periorbita), presence of PNI, or either recurrent or residual
disease after previous treatment.16,18
Adequacy of surgical margins. There is a correlation between the
diameter of a lesion and risk of recurrence. One study examining
margin status demonstrated that to obtain a 95% clear resectionmar-
gin rate for lesions 2 cm, a 4-mmmarginwas required, whereas for
Table 1. Prognostic Factors and Risk Stratification for NMSC of HN
Risk Factor Low Risk High Risk
Tumor size, cm  2  2
T stage T1-2 T3-4
Tumor thickness
(SCC), mm
 2  2 or Clarke level  4
Site Lip or mask areas of face
Differentiation Well Poor
Subtype (SCC) Basosquamous, desmoplastic,
or adenosquamous
PNI Absent or single
small nerve
Multifocal small nerve or
named nerve
Rapid growth Absent Present
Borders Well defined Poorly defined or in transit
LVSI Absent Present
Margin status Negative Positive
Immune status Immunosuppressed
Chronic inflammation
or scars (SCC)
Absent Present
Previous RT Absent Present
Abbreviations: HN, head and neck; LVSI, lymphvascular space involvement;
NMSC, nonmelanoma skin cancer; PNI, perineural invasion; RT, radiation
therapy; SCC, squamous cell carcinoma.
Primary treatment RT(topical/destructive
therapies for superficial 
lesions an option)
Negative marginsPositive margins
evresbOevresbO Postoperative RT
Low riskHigh risk*Low risk,
re-excision
clear
High risk*
or no further 
surgery
No surgery
Surgery
Fig 1. Treatment algorithm for primary site. RT, radiation therapy. (*) Figure 2
provides treatment algorithm for regional nodal basin.
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lesions  2 cm in diameter, a 6-mm margin was required.19 For
lesions  2 cm, a 10-mm minimum resection margin is generally
recommended, but this is often difficult to achieve in the HN, espe-
cially at depth.8 Table 2 summarizes tumor type, risk classification,
recommended minimum surgical margins, and 3-year local control
rates.
Radiation therapy. Although radiation therapy (RT) is predom-
inantly used in the adjuvant and palliative settings, it is an accepted
alternative definitive treatment where surgery is contraindicated, im-
practical, or not preferred. Despite its use, there is a paucity of high-
level evidence supporting an optimal RT technique, dose, and
fractionation schedule. Small lesions ( 2 cm) are more commonly
treatedwithhypofractionatedRT,with excellent control rates.Amore
fractionated course is typicallyused for larger lesionsorwhereoptimal
cosmetic results are desirable.8,20 Cognetta et al,21 examining more
than 1,700 patientswithNMSC treatedwith superficial x-ray therapy,
reported 2- and 5-year control rates of 98.1% and 95%, respectively.
Similar to surgical margins, recommended clinical target vol-
umes tend to be smaller for low-risk lesions (5 to 10 mm) and wider
for larger high-risk lesions ( 10 mm).20,22 Table 3 lists recom-
mended RT doses and fractionation schedules based on treatment
intent.
Destructive and topical therapies. Destructive and topical thera-
pies are typically used for actinic keratoses and SCC in situ, but they
may also be used in certain circumstances in superficial low-risk le-
sions. However, their use may result in inferior cure rates and mask
deeper recurrences.Not all treatments are supported by evidence, nor
have all been approved by theUS Food andDrugAdministration. US
Food and Drug Administration–approved treatments include 5%
imiquimodand5%Efudex (topical fluorouracil;ValeantPharmaceu-
ticals, Costa Mesa, CA), photodynamic therapy, and cryotherapy.
Other treatment options, such as intralesional agents, are considered
off label andoftenhave limitedevidence to support their efficacy.8,23,24
Locoregionally Advanced Disease
High-risk local disease. Where the only high-risk feature is a
positive margin, further surgery should be attempted to achieve local
control with single-modality treatment. Only in cases where further
surgery is not preferred, such as where it is likely to cause disfigure-
ment, should adjuvant RT (aRT) be considered (Fig 1).
Role of aRT. Because of the lack of high-level evidence confirm-
ing thebenefitof aRT, there arenouniversally adoptedguidelines as to
the presence of which adverse prognostic factors warrant adjuvant
therapy. Therefore, its use is predominantly based on clinician prefer-
ence and institutional policy. Accepting the inherent selection bias,
retrospective series on the use of aRT have demonstrated a reduction
in locoregional recurrence rates for advanced disease, and aRT is
considered in patients with T3-4 disease, regional nodal involvement,
clinical PNI (cPNI), and immunosuppression.25,26
In the TROG 05.01 (Trans Tasman RadiationOncology Group)
randomized trial (ClincalTrials.gov identifier NCT00193895) exam-
ining the role of aRT (60 to 66 Gy over 6 to 6.5 weeks in daily 2-Gy
fractions) with or without weekly concurrent chemotherapy (carbo-
platinumarea under curve 2) in high-risk cSCC, high-risk diseasewas
defined as either locally advancedprimarydisease (T3-4 [according to
AJCC or UICC] or in-transit disease) or high-risk nodal disease (any
of the following: extracapsular extension [ECE] of any node size,
intraparotid nodal metastasis regardless of size or number,  two
cervicalnodes, and/or cervicalnode3cm).Results are expectedmid
2016.
Regional lymph nodes. Intraparotid and cervical nodes are the
most common regional nodal basins involved in cSCCof theHNand
are typically staged with either CT and/or PET-CT. Risk of occult
regional nodal disease is based on the presence of primary-site high-
risk features. The decision of when to offer elective treatment is often
arbitrary, with many considering a 15% to 20% perceived risk of
occult disease as the trigger for therapy. In addition, surgical series
Table 2. Tumor Type, Risk Classification, Recommended Minimum Surgical
Margin, and 3-Year Local Control Rates
Tumor
Type
Recommended Minimal
Margin (mm)
3-Year Local
Control (%)
BCC
Low risk 2 to 4  98
High risk 4 to 10 90 to 95
SCC
Low risk 4 to 6 mm 80 to 95
High risk  10 60 to 80
Abbreviations: BCC, basal cell carcinoma; SCC, squamous cell carcinoma.
Table 3. Recommended RT Dose and Fractionation Schedule Based on
Treatment Intent for NMSC
Intent Dose (Gy)† Fractionation
Times per
Week
Primary definitive
 2 cm 24‡ 4 1
35 5 3 to 5
45 10 to 15 5
50 20 5
 2 cm 50 to 55 20 5
64 32 5
66 33 5
Primary
postoperative,
high risk
Negative margins 50 20 5
60 30 5
Positive margins As per primary definitive
Regional nodes,
unresected§
66 5 5
70 35 5
Regional nodes,
resected
As per primary postoperative, negative margins
66¶ 33 5
Regional elective
(SCC)
Postoperative N0 50 25 5
Surgical bed# 54 27 5
Abbreviations: NMSC, nonmelanoma skin cancer; RT, radiation therapy; SCC,
squamous cell carcinoma.
Higher doses tend to be used for SCC compared with basal cell carcinoma
for equivalent tumor size and extent.
†Choice of RT technique (eg, superficial x-ray therapy) dependent on tumor
and patient factors.
‡Superficial lesions ( 4 mm, superficial x-ray therapy, or orthovoltage).
§Role of concurrent chemotherapy adopted but unproven in cutaneous SCC.
No evidence of dose intensification or addition of chemotherapy in presence
of extracapsular extension for NMSC.
¶Consider for extracapsular extension.
#As per TROG 05.01 (Trans Tasman Radiation Oncology Group) protocol
(ClinicalTrials.gov identifier NCT00193895).
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have shown that in the presence of intraparotid nodal disease, the risk
of synchronous occult cervical nodal disease is approximately 15% to
20%, justifying theneed for electiveneck treatmentwitheither surgery
or RT.27
Given thevariabilityofdraining lymphnodes in cSCCof theHN,
sentinel lymph node biopsy (SLNB), with a reported positive predic-
tive value of 90% and negative predictive value of 95% to 98% in
cSCC,maybehelpful inguiding furthermanagement andavoidingan
unwarranted neck dissection.28 However,more studies supporting its
routine use are required.
Type of surgery—elective or therapeutic—depends on the loca-
tion of the primary site and potential or clinically or radiologically
evident sites of nodal spread. Interestingly, 10% to 15%will not have
an identifiable synchronous or metachronous index lesion.25
Role of adjuvant therapy. Figure2 shows the treatmentalgorithm
for the regional nodal basin. Depending on the nodal risk factors
present, reported regional relapse rates after therapeutic surgery alone
range between 20% and 80%.25 Multiple series have reported predic-
tors of regional recurrence, including size of involved nodes 3 cm,
multiple involved nodes ( two nodes), ECE, close or positive
margins, dermal nodal infiltration, in-transit disease, invasion of sur-
rounding structures such as bone or nerves, and immunosuppres-
sion.25 Reporting on the 5-year disease-free survival in patients with
metastatic cSCC to lymph nodes, Veness et al29 found a statistically
superior outcome in patients undergoing surgery and receiving aRT
compared with surgery alone (73% v 54%; P  .004). However,
Ebrahimi et al30 identified a low-risk subset of patients with a 3-year
DSSof97%after surgeryalone to theparotidbedand/or cervicalneck;
thesepatientshadone involvednode3cminmaximaldiameterand
no ECE.
Despite the lack of confirmatory randomized evidence justifying
itsuse, anumberof institutionshaveadoptedpostoperative chemoRT
in selected cases, such as those involving patients with ECEor positive
margins, basedonfindings fromrandomized studies demonstrating a
benefit in high-risk mHNSCC.31,32 NCCN guidelines recommend
concurrent postoperative chemotherapy, cisplatin (100 mg/m2 every
3weeksor30mg/m2weekly), andRT(60 to66Gyover6 to6.5weeks)
in the presence of extensive ECE ormultiple involved nodes.4
Systemic Treatment for Advanced SCC
There are no universal evidence-based guidelines for the man-
agement of patients with medically or surgically inoperable locally
advanced cSCC, recurrent disease after previous treatment, or pres-
ence of distantmetastatic disease. Cohort series and case reports have
reported activity with cisplatin, carboplatinum, fluorouracil, capecit-
abine, bleomycin, methotrexate, doxorubicin, paclitaxel, and do-
cetaxel. These can be used either as single agents or in combination,
with response rates up to 80%andmedian duration of approximately
4 to 6months.33One small prospective study reported an 86%overall
response ratewith concurrent carboplatinumandRT in patients with
locally advanced cSCC ineligible for surgery.34
Biologic therapies such as interferon alfa and 13-cis-retinoic acid
also demonstrate tumor response as single agents and in combination
after chemotherapy.33 Recent studies examining the role of anti–epi-
dermal growth factor receptor (EGFR) agents such as cetuximab and
panitumumab have reported disease control rates of approximately
70%.35,36 Because of lownumbers of unresectable ormetastatic cSCC,
the frequency of EGFR expression in cSCC is relatively unknown. The
relationship between prognosis and response to therapy and EGFR
overexpression, gene copynumber, andprotein expression is yet to be
fully evaluated. Unlike in metastatic colorectal cancer, there seems to
benoprovenassociationwithKRASorBRAFmutations and response
to anti-EGFR therapies.33
Aphase II study recently closed to accrual examined the addition
of erlotinib in the neoadjuvant and adjuvant settings, with planned
surgery or definitive RT for locally advanced disease (ClinicalTrials
.gov identifierNCT01059305).Currently accruing are aphase II study
examining the addition of concurrent cetuximab to aRT (Clinical
Trials.gov identifier NCT01979211) and a study examining cetux-
imab as preoperative treatment for high-risk cSCC (ClinicalTrials.gov
identifier NCT02324608).
Special Considerations
PNI. PNI is seenmore frequently in SCC (5% to 10%), where it
is associatedwith greatermorbidity andmortality than inBCC(2%to
5%).37Manypatientswith cPNIhavenoprecedinghistoryof inciden-
tal (pathologic)PNI (pPNI).The trigeminal and facial nerves aremost
commonly affected in cases of cPNI, which typically involves retro-
grade progression. Extratumoral disease, large-diameter nerve in-
volvement, and multifocal PNI are associated with more aggressive
behavior.37Recent evidence supports targetedMRIusing3-Teslaneu-
rography as the investigation of choice in the evaluation of cPNI.38
There is an important prognostic distinction between pPNI and
cPNI. Jackson et al39 reported improved 5-year local control (90% v
57%;P .0001) andDSS (90% v 76%;P .002) for pPNI compared
with cPNI, respectively, after treatment.
The additional benefit of aRT in themanagement of PNI, partic-
ularly in pPNI, is inconclusive.40 However, because of poor outcomes
with surgery alone with cPNI, aRT is commonly recommended.39,41
From an operability perspective, cPNI is subdivided into three zones,
relating toproximityofdisease to the skull base.Withmodern surgical
Clinically/radiologically node
negative, risk of nodal 
involvement considered 15%–20%
Therapeutic
Regional nodes for high-risk SCC (rarely BCC)
Postoperative RT for any of the following:
• ≥ 3 cm node
• ≥ 2 nodes
• ECE
• Positive margins
• Dermal or in transit metastases
• Invasion into surrounding structures (eg, bone)
*SLNB also an option
o Positive, regional nodal treatment
o Negative, observation 
Nodal
irradiationParotidectomy
and/or
neck dissection
Radical RT with or
without chemotherapy when  
surgery not preferred
Clinically/radiologically 
positive intraparotid and/or
cervical nodes
Elective
 treatment*
Fig 2. Treatment algorithm for regional nodal basin. BCC, basal cell carcinoma;
ECE, extracapsular extension; RT, radiation therapy; SCC, squamous cell carci-
noma; SLNB, sentinel lymph node biopsy.
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techniques, tumors previously considered unresectable, such as those
with extension up to the Gasserian ganglion (zone two), may nowa-
days be considered surgical candidates with the potential of improved
DSS and acceptable morbidity.42 The use of highly conformal RT
techniques, such as intensity-modulated RT, may provide durable
local control with lower long-term complications rates. In a study by
Balamucki et al,43 RT alone for inoperable cPNI resulted in a 5-year
local control rate of 54%, which was comparable to that in patients
with operable tumors receiving aRT. The role of elective nodal treat-
ment and/or adjuvant chemoRT in cPNI in the absence of other
adverse prognostic factors remains inconclusive.
Immunosuppression. Recipients of solid-organ transplants have
a 65- to 250-fold increased risk of developing a cSCC compared with
the general population.5 Tumors develop at a younger age, withmany
exhibiting high-risk features. Reduction in the level of immunosup-
pression depending on type of transplantation should be considered
in these patients.8 In a study of patients with node-negative cSCC and
chronic lymphocytic leukemia, regional recurrence occurred in 36%
and disease-specific death in 33%, despite surgery and aRT.44
Follow-Up and Surveillance
Ongoing monitoring after treatment is commonly based on the
treating clinician or institution policy and patient and tumor risk
factors. NCCN guidelines provide detailed recommended follow-up
policies for NMSC.4
BCC
Etiologic Factors
With the addition of nevoid basal cell carcinoma (NBCC) syn-
drome (Gorlin syndrome), the causative factors for the development
of BCCs are essentially similar to those of cSCC.
Clinical Features and Diagnostic Workup
There are four distinct clinical subtypes: nodular (most common
subtype), superficial, morphoeic (fibrosing), and fibroepithelial (fi-
broepithelioma of Pinkus). Confusion arises when histopathologic
patterns such as cystic, micronodular, and basosquamous BCC be-
come entwined with clinical subtypes.7
Early lesions and thosewith subtle changes on the background
of sun-affected skin can be difficult to diagnose. Evidence supports
the role of dermoscopy performed by a skilled clinician to increase
the accuracy of clinical diagnosis and assist in distinguishing a
lesion from other nonpigmented lesions and a melanoma from a
pigmented BCC.8
Staging
Thecurrent stagingclassification is the sameas that for cSCC,but
with limited prognostic utility because of its lowmetastatic potential.
Prognostic Factors
Prognostic factors are summarized inTable1.Mortality resulting
from BCC is quite rare, and when it does occur, it is primarily associ-
ated with either immunosuppression, NBCC syndrome, and/or ne-
glected tumors. The age-adjusted mortality rate is estimated at 0.12
per 100,000.7
Treatment
Recommended surgical margins are usually smaller than
those for cSCC of the same size.45 Table 2 lists recommended
minimum surgical margins. Figures 1 and 2 provide a summary of
treatment algorithms.
RT. RT is an effective alternative treatment where surgery
may be difficult or not preferred. A comprehensive review of the
role of RT in BCC by Cho et al46 reported high cure rates (79% to
100%), with 90% experiencing excellent cosmetic results (when
recorded). Control rates were comparable to published outcomes
with MMS, standard surgery, photodynamic therapy, and curet-
tage and electrodissection.
aRT is seldom required, but it is considered for high-risk lesions,
for recurrent disease, or where further surgery in the presence of
positive margins would be associated with marked morbidity, such
as disfigurement.20
Systemic therapy. Amajority of BCCs, either sporadic or associ-
atedwithNBCC syndrome, have enhanced hedgehog signaling, often
because ofmutations in the tumor suppressor genepatch-1 (PTCH 1)
and less commonly the smoothened gene (SMO).47
A recent development has been the successful targeting of the
hedgehog pathwaywith smoothened inhibitors.47-49 In a randomized
study, vismodegib was found to significantly reduce the BCC burden
and inhibit growth of new BCCs in patients with NBCC syndrome.
However, justmore thanhalf of patients had todiscontinue treatment
because of adverse events.47 Results of SMO inhibitor clinical trial
outcomes in BCC are listed in Table 4.
Systemic therapy has a potential role in the rare entity of meta-
static BCC and in locally advanced ormultiple BCCs, either preoper-
atively or as palliative treatment. A review of 53 aggregated cases
reported an 83% response rate with platinum-based chemotherapy,
37%being complete, andmedian time to progressionof 24months.50
EGFR is expressed in approximately 38% of BCCs, and activity with
cetuximab has been seen in case reports where platinum-based che-
motherapy had previously failed.51
MCC
Etiologic Factors
Themajor etiologic factor is chronic UV solar exposure; Merkel
cell polyomavirus (MCV or MCPyP), recently identified, is also pos-
tulated to be causative.52,53 MCC is highly immunogenic, with a
greater incidence in immunosuppressed patients.54
It has been suggested that the prevalence of MCV may vary in
distinct geographic locations and possibly reflect differences in treat-
ment outcomes. There is evidence that suggests virally associated
MCC in Australia is less common compared with other regions. A
study comparing 16 North American with 21 Australian patients
reported a 69% versus 24%prevalence for the virus, respectively.55 In
contrast, a study comparing 136 German with 38 Australian patients
documentednodifference (85.3% v86.8%, respectively).56 Inanother
series of 104 Australian patients, only 18.3% of patient cases were
positive for MCV, with an even lower rate (7.7%) for tumors in
sun-exposedHN locations versus non-HN sites.57 Although evidence
is inconclusive, it is plausible that the etiology of MCC in the Austra-
lian population is more a result of UV-associated rather than virally
associated carcinogenesis, comparedwith other geographic locations.
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Clinical Features and Diagnostic Workup
Skin lesions generally growrapidlyover a fewweeks, appearingas
red, pink, blue, or violet lesions. The incidence of occult or clinically
evident nodal metastases at presentation ranges between 30% and
50% and 20% to 25%, respectively.6,58
Staging and Prognosis
Current T stage is classified by tumor size or extension into
surrounding structures (T1, 2 cm; T2, 2 to 5 cm; T3, 5 cm; T4,
invasion to bone,muscle, fascia, or cartilage).11 Stages I (T1N0) and II
(T2-4N0) are further categorized (as A or B) depending on whether
nodeshavebeenevaluatedpathologicallyorclinically,on thebasis that
patients with pathologically evaluated negative lymph nodes experi-
encebetter survival comparedwithclinicallynode-negativepatients.59
Ofnote, 10%to15%ofpatientswill havenodalmetastaseswithout an
identifiable primary lesion and seem to experience better prognosis
comparedwith thosepresentingwitha synchronousormetachronous
primary lesion.60 MCC also has a high rate of distant spread, with a
disease-specificmortality rate of 25% to 50%.6 Presence of lymphvas-
cular space involvement has been shown to be highly predictive for
DSM.61 The prognostic significance of the presence of MCV remains
unclear, with some authors suggesting a better DSS in MCV-positive
patients.53 MCV-specific CD8 T cells can be detected in the blood of
patientswithMCC,which seems to correlatewith disease progression
and response to treatment.62 Afanasiev et al62 reported programmed
death ligand 1 (PD-L1), which is associated with diminished host
antitumor immune response, was expressed in nine of 13 MCCs
tested. Dowlatshahi et al63 reported that subsets of immune cells
within MCC expressed PD-1, PD-L1, and PD-L2, and infiltrating T
cells showed reduced activation, evidencedbydecreased expressionof
CD69 and CD25. A number of immune checkpoint inhibitors are
being assessed in clinical trials, such as the PD-1 antibody pembroli-
zumab (ClinicalTrials.gov identifier NCT02267603), anti–PD-L1
MSB0010718C (ClinicalTrials.gov identifier NCT02155647), and
anti–CTLA-4 ipilumimab (ClinicalTrials.gov identifierNCT02196961).
PET scanning seems useful in the staging of MCC. In a study by
Sivaetal,64PETstaginghadan impactonmanagement inalmost40%,
including upstaging in 17%.Onmultivariable analysis, PET stage was
significantly associated with overall survival (P .001).
Treatment
Local disease. Treatment recommendations are generally based
on single-institution retrospective studies with data collected over
many years. As a result, there are variations in treatment philosophy,
particularly with respect to the need for aRT.
Wide local excision remains a standard approach, with a 1- to
2-cm minimum margin recommended for small lesions ( 2 cm).
Although aRT in the presence of closemargins has shown to lower the
risk of local recurrence, some omit its use for small lesions with wide
margins ( 1 cm) and no other adverse features.65,66 Despite the lack
of randomized studies, RT is an effective alternative to surgery, result-
ing in high (75% to 85%) in-field control rates.67 Proponents of
combined treatment advocate margin-negative surgery, without the
need for wide margins, followed by aRT.68
Regional lymph nodes. Patient selection for elective nodal treat-
ment remains a clinical dilemma. Tumor size is an important predic-
tor of occult nodal disease. However, even small lesions harbor a 15%
to 20% risk of nodal involvement, supporting the need for either
pathologicnodal assessmentorelective therapy inmanycases.69 SLNB
offers the potential to assess regional nodes for occult disease and
appropriate selection for further treatment.65
Table 4. SMO Inhibitor Clinical Trial Outcomes in BCC
Cohort No. of Patients Response Rate (%)
Reduction in New
Lesions
Median Duration of
Response (months)
Serious AE
Rate (%)
Discontinue
Rate (%)
Patient
Choice AE
Vismodegib (metastatic)49 33 Response, 30; composite of
RECIST and
measurement of external
dimensions and
ulceration
NA Independent review, 7.6;
investigator
assessment, 12.9
25 6 12
Vismodegib (locally
advanced)49
63 CR, 21; overall response,
43
NA Independent review and
investigator
assessment, 7.6
25 25 12
Vismodegib (NBCC
syndrome)48
41 (active drug, 26;
placebo, 15)
Mean reduction in size of
existing BCC, 65% v
11%; no progression
seen with vismodegib
2 (active) v 29
(placebo) new
lesions per
year
8 40 NA 54
Sonidegib (locally advanced)
200 mg50
66 CR, 3; PR, 44; DCR, 91 NA Median PFS not
reached; 12-month
EFP, 83%
14 21
Sonidegib (metastatic) 200
mg50
13 CR, 0; PR, 15; DCR, 93 NA PFS, 13.1; 12-month
EFP, 65%
14 21
Sonidegib (locally advanced)
800 mg50
128 CR, 0; PR, 35; DCR, 78 NA Median PFS not
reached; 12-month
EFP, 86%
30 36
Sonidegib (metastatic) 800
mg50
23 CR, 0; PR, 17; DCR, 83 NA PFS, 10; 12-month EFP,
16%
30 36
Abbreviations: AE, adverse event; BCC, basal cell carcinoma; CR, complete response; DCR, disease control rate (defined as % of patients with CR, PR, and stable
disease); EFP, event-free probability; NA, not applicable; PFS, progression-free survival; PR, partial response.
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Patients with a positive SLNB should proceed to either lymph-
adenectomy or regional RT.4 Because most patients with nodal me-
tastases will still be candidates for nodal aRT—particularly in the
setting of multiple nodes, ECE, and close soft tissue margins—
synchronous RT to the primary site and elective nodal basin without
performing a lymphadenectomy may be considered, avoiding
combined-modality treatment to the neck.
RTdoses are generally lower forMCCthan forNMSCbecauseof
increased radioresponsiveness.Doses range from60 to 66Gy for gross
disease, 56 to 60 Gy for microscopic disease, 50 to 56 Gy for clear
margins, and 46 to 50Gy for elective nodal treatment, in convention-
ally fractionated 2-Gy doses.4
Systemic therapy. Despite effective locoregional therapy, 30%
to 70%of patients will experience distant relapse.70 Chemotherapy
in the definitive setting remains unproven.71 As in small-cell carci-
noma of the lung, carboplatinum and etoposide have been used.
Single-arm studies of chemotherapy with or without RT in MCC
have documented feasibility and efficacy.70 However, a recent large
retrospective survival analysis did not show a benefit from adjuvant che-
motherapyforstageIIIdisease.72Inaddition,manypatientsareolderwith
comorbidities and unable to tolerate chemotherapy. A phase II study to
evaluate the efficacy of chemoRT in achieving locoregional control and
the value of PET in staging, RTplanning, and treatment response assess-
ment is currentlybeingconducted(TROG09.03;ClinicalTrials.gov iden-
tifierNCT01013779).
Response rates of 60% to 70% have been demonstrated with
palliative chemotherapy.73 Other potential targets include antiapop-
toticagents, inhibitorsof c-Metandvascularendothelial growth factor
receptor 2, and agents directed toward somatastatin receptors.
SUMMARY
Despite the frequency of NMSC, there remains a lack of high-level
evidence in themanagement of locally advanced disease, and patients
with complex cases warrant referral to MDT boards. Retrospective
series support consideration of aRT in the presence of advanced pri-
mary disease (T3-4), regional nodal involvement, cPNI, and immu-
nosuppression. MCC is a highly aggressive disease that carries a poor
prognosis and remains a therapeutic challengebecauseof thehigh rate
of nodal and distant relapse.
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